What is the official ID of this bill?

The official print number for this legislation is S 2329.

When did the legislative process begin?

The process officially started on 2023-07-13.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/s2329/BILLS-118s2329is.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Who is the primary sponsor?

The primary sponsor is Sen. Hickenlooper, John W. [D-CO].

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Analysis and Potential Impact of S 2329

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

FDA Program to Accelerate Vaccine and Drug Approval for Future Pandemics.

Q: What are the main provisions?

Key points include: Establishes a dedicated FDA program to speed up the review and approval process for new vaccines and treatments during potential pandemics. Activities include advancing scientific research, monitoring countermeasure safety, and prioritizing the development of platform vaccine technologies. Authorizes $60 million per year (FY 2024–2028) to fund these preparedness efforts, focusing on national health security.

This Act establishes a new preparedness program within the FDA to streamline the development and approval of medical countermeasures, such as vaccines and treatments, against emerging pathogens. This initiative aims to enhance public health security by ensuring faster access to approved medical solutions during future health crises. The program is authorized to receive $60 million annually from 2024 through 2028.

Key points

Establishes a dedicated FDA program to speed up the review and approval process for new vaccines and treatments during potential pandemics.

Activities include advancing scientific research, monitoring countermeasure safety, and prioritizing the development of platform vaccine technologies.

Authorizes $60 million per year (FY 2024–2028) to fund these preparedness efforts, focusing on national health security.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Emerging Pathogen Preparedness Program Authorization Act

Print number: S 2329

Sponsor: Sen. Hickenlooper, John W. [D-CO]

Process start date: 2023-07-13

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-09-2025

Source data: api.congress.gov

AI work logs for this document launch

FDA Program to Accelerate Vaccine and Drug Approval for Future Pandemics.

Key Questions about FDA Program to Accelerate Vaccine and Drug Approval for Future Pandemics.